AQST — Aquestive Therapeutics, Inc.
Is AQST overbought or oversold? Here is the current MarketMoodz read.
Aquestive Therapeutics, Inc. (AQST) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $3.76. The rating moved from Strong Oversold to Oversold on November 14, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$3.76
- Last changeMoved from Strong Oversold to Oversold on November 14, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all oversold Healthcare stocks →
AI analysis
Aquestive Therapeutics, Inc. (AQST) is a small‑cap specialty drug‑delivery company with technologies that could capture readthrough benefits from a market shift toward at‑home and outpatient treatment modalities. The company’s commercial and partnership prospects are the primary near‑term value drivers, while sector interest in defensive large‑cap pharma and specialty distribution may improve strategic partnership opportunities. Financial health and runway remain key monitoring points; limited liquidity and the high probability of future financing/dilution increase downside risk. Short‑term performance is likely catalyst‑driven, tied to regulatory, commercial and licensing developments. Investors should weigh meaningful upside from successful commercialization against elevated execution and financing risks.
Key factors
- Proprietary drug-delivery technologies position the company to benefit from readthroughs favoring at‑home and outpatient modalities (e.g., sublingual/film and patch delivery innovations).
- Commercial-stage products or near-term commercialization opportunities can provide revenue and partnership leverage versus earlier-stage biotechs.
- Sector backdrop is constructive for specialty delivery and large‑cap pharma defensive flows, which can help partnerships and licensing interest.
- Market sensitivity to earnings and news-driven flows implies short-term price moves will be catalyst-driven rather than macro-driven.
- Smaller-cap profile with potential for meaningful upside on positive regulatory, commercial or partnership announcements.
Risks
- Clinical or regulatory setbacks for product candidates or delivery platforms would materially damage valuation.
- Limited liquidity and cash runway typical of small biopharma; likely need for additional capital could dilute shareholders.
- Competitive pressure from large pharmaceutical companies and device makers adopting similar at‑home delivery formats.
- Reimbursement, payer adoption and formulary access risks for novel delivery formats could constrain commercial uptake.
- Operational and manufacturing scale-up challenges that could delay launches or increase costs.
- Convertible debt or financing activity in the sector increases dilution and hedging-driven selling pressure for mid/small caps.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for AQST — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.